Osler Diagnostics

What Osler Diagnostics does

Osler Diagnostics is a UK-based medical diagnostics company founded in 2017 as a spin-out from the University of Oxford, headquartered in Oxford and operating as a private limited company. The company is developing a single core product platform — the Osler Origin, a portable "lab-in-a-hand" diagnostic device intended to deliver lab-quality, quantitative, accurate, sensitive, and multiplexed testing at the point of care. The platform is built on proprietary Osler HemaTap sample addition technology, microfluidic sample preparation, and electrochemical biosensing, drawing on decades of Oxford University research in the chemistry department that originally pioneered the portable electrochemical blood glucose sensor. The technology is protected by a comprehensive intellectual property portfolio, including registered trademarks for Osler, Osler Origin, and HemaTap.

The Osler Origin is positioned to consolidate multiple existing diagnostic systems onto a single instrument, offering a comprehensive test menu across Emergency Departments, Doctor's Offices, Retail Pharmacies, and other healthcare settings globally. The intended business model is a razor-and-blade construct: hardware sale of the instrument paired with recurring revenue from consumable test cartridges and reagents — a typical model for point-of-care diagnostics. Pricing is not publicly disclosed, and the company plans to pursue direct enterprise sales to healthcare institutions.

As of January 2026, Osler had raised over £145 million across multiple funding rounds from institutional and strategic investors (M&G Investments, Oxford Science Enterprises, Braavos Investment Advisers, Lansdowne Partners) and employed approximately 150 staff. The company is pre-revenue: the Osler Origin product was completed in 2022 and is advancing through regulatory approvals in major geographies ahead of market launch. The January 2026 transition from co-founder Connor Campbell to diagnostics industry veteran John Sperzel as CEO explicitly signals a strategic shift from R&D-led development to commercial execution.

Name

Osler Diagnostics

Legal name

Osler Diagnostics Limited

Website

https://oslerdiagnostics.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

101–250 employees

Short description

Osler Diagnostics is a UK-based medical diagnostics company developing the Osler Origin, a portable "lab-in-a-hand" electrochemical biosensing platform that delivers lab-quality, multiplexed point-of-care testing across emergency departments, doctor's offices, and retail pharmacies globally.

Ownership category

akta.pro rank

Product category

Point-of-Care Diagnostics

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Analytical Laboratory Instrument Manufacturing (334516)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers) (HLAHACAL)

akta.pro secondary industries

Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices) (HLACAPAK), Home-Use & OTC Rapid Self-Tests (Consumer POCT kits) (HLAHAOAK)

Keywords

• Point-of-care diagnostics
• Portable diagnostic devices
• Electrochemical biosensing
• Microfluidic sample preparation
• Blood diagnostic testing

Headquarters

HQ city

Oxford

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain

Revenue model

1. Diagnostic Device Sales: Sale of the Osler Origin portable diagnostic platform and associated test cartridges to healthcare providers globally
2. Diagnostic Consumables: Recurring revenue from sale of test cartridges and reagents for the Osler Origin platform - typical consumables model for point-of-care diagnostics

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Core offering

Osler Diagnostics develops and manufactures the Osler Origin, a portable "lab-in-a-hand" diagnostic platform that consolidates multiple testing systems onto a single instrument. It uses proprietary Osler HemaTap sample addition, microfluidic sample preparation, and electrochemical biosensing to deliver lab-quality, quantitative, accurate, sensitive, and multiplexed diagnostic testing at the point of care. The platform is sold to healthcare providers across Emergency Departments, Doctor's Offices, Retail Pharmacies, and other global healthcare settings.

Product overview

Osler Diagnostics offers a single unified product platform: the Osler Origin, a portable diagnostic device that functions as a 'portable lab.' The device provides comprehensive diagnostic testing capabilities including sample addition via proprietary HemaTap technology, microfluidic preparation, and electrochemical biosensing. Designed for use across Emergency Departments, Doctor's Offices, and Retail Pharmacies, the Osler Origin consolidates multiple testing systems onto a single instrument, offering high-performance quantitative, accurate, sensitive, and multiplexed testing in a portable, low-cost, fast, and easy-to-use format.

Differentiator

Problem solved

Functional benefit

Brands

• Osler Origin: A portable diagnostic platform, described as a 'portable lab', capable of providing lab-quality diagnostics to anyone, anywhere, at any time across a wide portfolio of diagnostic tests.
• Osler HemaTap

Products and services

• Osler Origin

Quantifiable outcome

• Step-change in portable diagnostics going beyond existing solutions limited in test menu and performance
• +1 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Scale indicators7 records

Recent moves6 records

Expansion highlights7 records

Broad incumbents

• Siemens Healthineers: Diversified diagnostics and imaging major with POC and laboratory testing portfolios; relevant incumbent comparable in the broader hospital diagnostics market Osler targets.
• Abbott: Global diagnostics leader with the i-STAT and other POC platforms across hospitals, physician offices, and retail; directly comparable as the dominant incumbent Osler must compete against in portable diagnostics.
• Werfen: Specialty diagnostics company owning Instrumentation Laboratory and Accriva Diagnostics; comparable as incumbent in acute-care and POC diagnostics, and former employer of Osler CEO John Sperzel.
• Roche Diagnostics: World's largest in-vitro diagnostics company with broad POC and central-lab offerings; comparable as a dominant incumbent in clinical diagnostics and former employer of Osler's board director Roland Diggelmann (former CEO).
• Cepheid (a Danaher company): Leader in molecular diagnostics with the GeneXpert system deployed across hospitals and near-patient settings; comparable as a higher-performance molecular POC incumbent whose clinical footprint Osler could eventually encroach upon.

Direct peers

• Nova Biomedical: Privately held manufacturer of blood glucose, critical care, and POC analyzers; directly comparable as an established POC-focused mid-cap competitor to Osler.
• EKF Diagnostics: UK-listed POC and clinical chemistry diagnostics company with point-of-care analyzers and reagents; directly comparable as a similarly sized POC-focused competitor serving hospitals and physicians' offices.
• Chembio Diagnostics: POC diagnostics company focused on infectious disease rapid tests; directly comparable as a specialty POC competitor and former employer of Osler CEO John Sperzel (former CEO).
• QuidelOrtho: Specialist in rapid immunodiagnostics and POC testing including Sofia and Triage platforms; directly comparable as a focused POC diagnostics competitor targeting similar clinical settings.

Emerging players

• Binx Health: Developer of rapid molecular diagnostic testing platforms for clinical and at-home settings; comparable as a similarly staged emerging molecular POC peer focused on decentralized testing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/OslerDx
• YouTubeyoutube.com/channel/UCG2r49bePSJlhMLQnTvaDrA
• LinkedInlinkedin.com/company/oslerdiagnostics

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds5 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Osler Diagnostics